Prenetics Global Limited
NASDAQ:PREMedical - Diagnostics & Research
+$0.43 today
- Market cap
- $184.89M
- Beta
- 0.24
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$4.18
Volume 0.82M
Average 0.22M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Prenetics Global Limited
NASDAQ:PRE
Intrinsic Alpha fair value
Locked
Current Price
$10.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +91.5% | +53.3% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +91.5% over three years. Forward estimates point to Revenue at +53.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Profound Medical Corp. NASDAQ:PROF | $271.77M | $7.42 | Not rated | -6.3 | +12.07% |
OraSure Technologies, Inc. NASDAQ:OSUR | $249.95M | $3.62 | Not rated | -4.0 | +71.09% |
TriSalus Life Sciences, Inc. NASDAQ:TLSI | $149.93M | $2.43 | Not rated | -7.4 | -56.15% |
Armata Pharmaceuticals, Inc. AMEX:ARMP | $143.89M | $3.87 | Not rated | -0.9 | -58.32% |
Codexis, Inc. NASDAQ:CDXS | $127.03M | $1.16 | Not rated | -7.1 | -33.12% |
MaxCyte, Inc. NASDAQ:MXCT | $122.82M | $1.19 | Not rated | -3.2 | -21.47% |
Neuronetics, Inc. NASDAQ:STIM | $108.04M | $1.39 | Not rated | -2.3 | -4.62% |
Insight Molecular Diagnostics Inc. NASDAQ:IMDX | $70.03M | $2.14 | Not rated | -3.9 | -72.65% |
Atlantic International Corp. NASDAQ:ATLN | $68.61M | $0.90 | Overvalued | -0.6 | -63.11% |
Sangamo Therapeutics, Inc. NASDAQ:SGMO | $30.66M | $0.07 | Not rated | -0.5 | -54.55% |
Continue the stock analysis
Jump to another research area for this company.